Two Sigma Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-3,600
Closed -$237K 1499
2024
Q4
$237K Sell
3,600
-5,500
-60% -$368K 0.03% 829
2024
Q3
$640K Sell
9,100
-1,400
-13% -$117K 0.01% 1135
2024
Q2
$864K Buy
+10,500
New +$874K 0.01% 1164
2021
Q1
Sell
-8,800
Closed -$772K 917
2020
Q4
$772K Buy
+8,800
New +$698K 0.02% 491
2020
Q3
Sell
-13,800
Closed -$1.7M 1306
2020
Q2
$1.7M Buy
13,800
+8,300
+151% +$825K 0.04% 265
2020
Q1
$465K Sell
5,500
-3,000
-35% -$258K 0.01% 650
2019
Q4
$719K Buy
8,500
+1,700
+25% +$128K ﹤0.01% 1232
2019
Q3
$458K Buy
6,800
+900
+15% +$69.3K ﹤0.01% 1263
2019
Q2
$505K Buy
5,900
+2,900
+97% +$248K 0.01% 1111
2019
Q1
$266K Buy
+3,000
New +$278K ﹤0.01% 1272
2018
Q4
Sell
-2,100
Closed -$204K 2171
2018
Q3
$204K Sell
2,100
-1,800
-46% -$180K ﹤0.01% 2122
2018
Q2
$367K Sell
3,900
-5,600
-59% -$490K ﹤0.01% 1938
2018
Q1
$770K Buy
9,500
+5,000
+111% +$429K ﹤0.01% 1413
2017
Q4
$401K Buy
+4,500
New +$391K 0.01% 824

Other funds holding BMRN

Two Sigma Securities's BMRN Position: Q1 2026 in Review

Two Sigma Securities opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 22,096 shares worth $1.25M. The stake represents 0.15% of the portfolio and ranks #166 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in BMRN as recently as Q2 2025.

Two Sigma Securities first reported a position in BMRN in Q2 2017 and has held it in 18 quarters since. The position peaked at $7.27M in Q3 2024. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Two Sigma Securities held 22,096 shares of BioMarin Pharmaceuticals worth $1.25M as of Q1 2026.
  • BioMarin Pharmaceuticals was a new Two Sigma Securities position in Q1 2026.
  • BioMarin Pharmaceuticals made up 0.15% of Two Sigma Securities's portfolio in Q1 2026, its #166 holding.
  • Two Sigma Securities first reported a position in BioMarin Pharmaceuticals in Q2 2017 and has held it in 18 quarters since.
  • Two Sigma Securities's BioMarin Pharmaceuticals position peaked at $7.27M in Q3 2024.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.